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we fear, however, that the article may have overstated the weakness of Hba 1c as a diagnostic test, especially in relation to fasting glucose levels.
First, although genetic differences undoubtedly contribute to variation in Hba 1c values, 2 the clinical significance of this genetic contribution is uncertain. the prior studies mentioned by Dagogo-Jack could not exclude the possibility that heritable dif ferences in Hba 1c stemmed from genetic differences in glucose metabolism as opposed to genetic differences in glucoseindependent processes, such as glycation tendency. in fact, the paper by snieder et al. 3 found the genetic contribution to fasting glucose was nearly as large as the genetic contribution to Hba 1c (51% versus 62%). the authors conclude "much of the variation in Hba 1c levels between individuals is inherited" 3 and that "elevated Hba1c levels may indicate an increased familial risk of diabetic micro vascular disease. " 3 in individuals with diabetes mellitus, true differences in glycemia far outweigh glucose-independent mechanisms in explaining Hba 1c variation.
second, prior studies of racial and agerelated differences in Hba 1c levels have accounted for single measurements of fasting and 2 h post-challenge glucose, but not for integrated levels of daytime nonfasting glycemia. Older individuals and ethnic minorities might possibly have differences in diet and physical activity that influence Hba 1c levels via real dif ferences in nonfasting glycemia. the fact that longitudinal studies have found Hba 1c levels equally predictive of long-term vascular and mortality risk in black and white indivi duals 4 supports the notion that black-white differences in Hba 1c are 'real' (that is, due to glycemia) rather than artefactual (owing to differences in glycation tendency or other mechanisms that are in dependent of glucose metabolism).
third, although we agree that, historically, important concerns were raised about many conditions that would interfere with measure ment of Hba 1c , this problem has been largely solved by new assay methods. the national Glycohemoglobin standardization Program works directly with manufacturers to certify test methods, implementing stringent requirements for accuracy and precision. 5 we certainly agree that conditions that substantially alter erythrocyte turnover can affect Hba 1c test results, regardless of measurement methodology-Hba 1c is definitely not perfect, but neither is glucose. the glucose assay is subject to diurnal variation, laboratory calibration problems, and pre analytical issues. 6 additional limitations of glucose testing include participant preparation (that is, fasting) and much greater within-person variation compared with Hba 1c levels. 7 Fourth, judging the sensitivity and specificity of Hba 1c against a glucose-based gold standard is misleading. Because glucose determinations are inherently more variable than Hba 1c , these convenient gold standards reduce the apparent accuracy of Hba 1c . a stronger comparison would rely on repeated glucose determinations on different days, and data suggest Hba 1c performs extremely well when diabetes definitions that reflect those used in clinical practice are used as the gold standard. 8 an even fairer-and more clinically meaningful-gold standard might be prediction of microvascular events, vascular events and mortality. against this unbiased standard, Hba 1c appears at least as strong as fasting glucose. 4, [9] [10] [11] [12] in conclusion, we recommend that the value of Hba 1c be judged on the basis of its predictive importance, a metric that subsumes these other concerns and puts it on equal footing with the alternatives. 
